Merck announced this morning that the latest individual state court Fosamax ONJ plaintiff in New Jersey was unable to prove that her jaw problems were primarily a result of the Merck drug.
I am on the road this week, and will return with more fullsome reports next week — including a great tidbit from a loyal reader — on how a recent study found that more Ezetimibe (branded as Merck’s Zetia) is worse than less, for some patients.
Be excellent to one another.
